Table 1.
Studies on Haploidentical Hematopoietic Stem Cell Transplantation
| Patients(n) | Disease | Conditioning | Graft/ Manipulation | GVHD Prophylaxis | GF | aGVHD | cGVHD | TRM | LFS/DFS | Nation | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 | AL | ST:TBI/thiotepa/fludarabine/ATG | PB/CD34+ selection | No | 1st 6.9% | (II-IV)7.9% | 7.1% | 36.5% | AL CR:46%-48% | Italy | Aversa (2005)[8] |
| 49 | AL/MDS/ CML/MPD | RIC: Flu+Cy/ anti-CD52 | PB/anti-CD52 | CsA+MMF | 6% | (II-IV)16% | 14% | 10.2% | 31-63%@1-3 year | U.S.A | Rizzieri (2007)[10] |
| 24 | AL/AA | ST:TBI/CY | BM/costimulatory blockade | CsA+MTX | 5% | (III-IV)23.8% | 8.3% | 50% | 33%@7 years | U.S.A | Guinan (2008)[11] |
| 60 | AL/NHL/ CML/MM | RIC:Flu/Mel/OKT-3/thiotepa | PB/CD3+CD19 depletion | No if CD3+T < 5 × 104/kg | 0 | (II-IV)47% | 15% | 25%@100 days 44%@7 years |
HR 41%@1 year 24%@2 years | Germany | Federmann (2009)[12] |
| 66 | AL/MDS | RIC:TBI/flu/Bu/ATG/melphalan | PB or BM/No | FK506 | 6.1% | (II-IV)38% | 33.3% | 59.1% | 28.8%@4 years | Japan | Kurokawa (2010)[13] |
| 820 | AL/CML/ NHL/AA | ST:Bu/Cy/Ara-C/MeCCNU/ATG | BM+PB/No | CsA+MTX +MMF | < 1% | (II-IV)42.9% (III-IV)14.0% |
Total 53.7% Ex 23.4% @2 years |
21%@2 years | SR68.1% HR47.1% @2 years |
China | Huang (2011)[14] |
| 83 | AL/MDS | RIC:Bu/Flu/ATG | PB/No | CsA+MTX | 0 | 24% | 28% | 17%@1 year | AML/MDS CR53%-60%; AML RE9% |
Korea | Lee (2011)[15] |
| 50 | AL/MDS | RIC:Cy/Flu/TBI | BM/No | Cy(HD)+ FK506+MMF | 4% | (II-IV)32% | 13% | 7%@1 year | 46%@1 year | U.S.A | Fuchs (2011)[9] |
| 21 | AL/CML | ST:Bu/Cy/ MeCCNU/ATG | PB/No | CsA+MTX +MMF | 0 | (II-IV)33.8% | 39.5% | 20%@2 years | 55.6%@2 years | China | Yu (2012)[16] |
HLA Human leukocyte antigen; AL Acute Leukemia; CML chronic myelogenous leukemia; MDS myelodysplastic syndrome; ST Standard intensity/Myeloablative; RIC reduced intensity; Bu Busulfan; Cy cyclophosphamide; Ara-C aracytidine; TBI total-body irradiation; MeCCNU Semustine; CsA cyclosporine A; MMF Mycophenolate mofetil; Flu fludrabine; ATG antithymocyte globulin; FK506 Tacrolimus; anti-CD52 alemtuzumab; GF graft failure; HR high risk; SR standard risk; Re refractory; Ex extensive; GVHD Graft versus host disease